Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257

1.

Consumer attitudes about opioid addiction treatment: a focus group study in New York City.

Sohler NL, Weiss L, Egan JE, López CM, Favaro J, Cordero R, Cunningham CO.

J Opioid Manag. 2013 Mar-Apr;9(2):111-9. doi: 10.5055/jom.2013.0152.

2.

Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.

Shah PA, Sohler NL, López C, Fox AD, Cunningham CO.

J Opioid Manag. 2013 Nov-Dec;9(6):407-13. doi: 10.5055/jom.2013.0183.

3.

Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.

Yarborough BJ, Stumbo SP, McCarty D, Mertens J, Weisner C, Green CA.

Drug Alcohol Depend. 2016 Mar 1;160:112-8. doi: 10.1016/j.drugalcdep.2015.12.031. Epub 2016 Jan 6.

4.
5.

Opioid agonist treatment for pharmaceutical opioid dependent people.

Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N.

Cochrane Database Syst Rev. 2016 May 9;(5):CD011117. doi: 10.1002/14651858.CD011117.pub2. Review.

PMID:
27157143
6.

Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.

Hser YI, Saxon AJ, Huang D, Hasson A, Thomas C, Hillhouse M, Jacobs P, Teruya C, McLaughlin P, Wiest K, Cohen A, Ling W.

Addiction. 2014 Jan;109(1):79-87. doi: 10.1111/add.12333. Epub 2013 Oct 9.

7.

"Should I stay or should I go?" Coming off methadone and buprenorphine treatment.

Winstock AR, Lintzeris N, Lea T.

Int J Drug Policy. 2011 Jan;22(1):77-81. doi: 10.1016/j.drugpo.2010.08.001. Epub 2010 Oct 16.

PMID:
20956077
8.

Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.

Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO.

Addict Sci Clin Pract. 2015 Jan 16;10:2. doi: 10.1186/s13722-014-0023-0.

9.

Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment.

Madden A, Lea T, Bath N, Winstock AR.

Drug Alcohol Rev. 2008 Nov;27(6):671-8. doi: 10.1080/09595230801935706.

PMID:
19378450
10.

Clinical factors associated with sexual dysfunction among men in methadone maintenance treatment and buprenorphine maintenance treatment: a meta-analysis study.

Yee A, Loh HS, Hisham Hashim HM, Ng CG.

Int J Impot Res. 2014 Sep-Oct;26(5):161-6. doi: 10.1038/ijir.2014.18. Epub 2014 Jul 3. Review.

PMID:
24990199
11.

Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.

Fox AD, Chamberlain A, Sohler NL, Frost T, Cunningham CO.

J Subst Abuse Treat. 2015 Jan;48(1):112-6. doi: 10.1016/j.jsat.2014.07.015. Epub 2014 Aug 7.

12.

Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.

Piralishvili G, Otiashvili D, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE.

J Subst Abuse Treat. 2015 Mar;50:32-7. doi: 10.1016/j.jsat.2014.10.003. Epub 2014 Oct 22.

PMID:
25456093
13.

Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system.

Gryczynski J, Jaffe JH, Schwartz RP, Dušek KA, Gugsa N, Monroe CL, O'Grady KE, Olsen YK, Mitchell SG.

Am J Addict. 2013 May-Jun;22(3):285-91. doi: 10.1111/j.1521-0391.2012.12004.x.

14.

A comparison of attitudes toward opioid agonist treatment among short-term buprenorphine patients.

Kelly SM, Brown BS, Katz EC, O'Grady KE, Mitchell SG, King S, Schwartz RP.

Am J Drug Alcohol Abuse. 2012 May;38(3):233-8. doi: 10.3109/00952990.2011.643983. Epub 2012 Jan 13.

15.

Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence.

Ridge G, Gossop M, Lintzeris N, Witton J, Strang J.

J Subst Abuse Treat. 2009 Jul;37(1):95-100. doi: 10.1016/j.jsat.2008.09.007. Epub 2008 Nov 11.

PMID:
19004598
16.

Buprenorphine versus methadone in pregnant opioid-dependent women: a prospective multicenter study.

Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C.

Eur J Clin Pharmacol. 2011 Oct;67(10):1053-9. doi: 10.1007/s00228-011-1049-9. Epub 2011 May 3.

PMID:
21538146
17.

The New Kid on the Block--Incorporating Buprenorphine into a Medical Toxicology Practice.

Wiegand TJ.

J Med Toxicol. 2016 Mar;12(1):64-70. doi: 10.1007/s13181-015-0518-4. Review.

18.

Medication-assisted therapy for opioid-dependent incarcerated populations in New Mexico: statewide efforts to increase access.

Trigg BG, Dickman SL.

Subst Abus. 2012;33(1):76-84. doi: 10.1080/08897077.2011.611455.

PMID:
22263716
19.

Methadone and buprenorphine for the management of opioid dependence in pregnancy.

Jones HE, Finnegan LP, Kaltenbach K.

Drugs. 2012 Apr 16;72(6):747-57. doi: 10.2165/11632820-000000000-00000. Review.

PMID:
22512363
20.

Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

Mattick RP, Breen C, Kimber J, Davoli M.

Cochrane Database Syst Rev. 2014 Feb 6;(2):CD002207. doi: 10.1002/14651858.CD002207.pub4. Review.

PMID:
24500948

Supplemental Content

Support Center